Citicoline: What the Clinical Trials Showed, and What They Did Not Settle

Abstract

Citicoline is the most clinically studied compound in our Clarity formulation, and it is the one with the most uncomfortable evidence. Two large trials designed to settle its value in acute brain injury returned negative results, and interest in the compound continued anyway.

This article follows three open-access reviews and one trial to establish what has actually been demonstrated. It also examines a pharmacological detail that receives almost no attention outside the specialist literature and which changes how the rodent evidence should be read.

Our conclusion is that citicoline has an unusually solid safety record, a plausible and partly confirmed mechanism, and a clinical record that does not support the confidence with which it is sold.

1.What the Compound Is Supposed to Do

Citicoline — cytidine 5′-diphosphocholine, also called CDP-choline — is an intermediate in the Kennedy pathway, the route by which cells build phosphatidylcholine, a principal component of neuronal membranes.

The rationale for supplementing it is that supplying an intermediate should support the production of membrane material, particularly where membranes are being damaged or rebuilt. That is why the compound was tested first in stroke and traumatic brain injury rather than in healthy people wanting sharper focus.

2.The Two Trials That Were Supposed to Settle It

ICTUS was an international, randomised, multicentre, placebo-controlled trial of citicoline in acute ischaemic stroke. More than two thousand patients participated, with over a thousand receiving citicoline for six weeks. It did not demonstrate benefit.

COBRIT, published in JAMA, tested citicoline in traumatic brain injury and likewise failed to show an effect on functional and cognitive status.

The 2014 review in CNS Drugs — whose title, tellingly, is 'facts, doubts and unresolved issues' — records that the negative outcomes of these pivotal studies were deemed surprising and prompted commentary focused largely on methodological aspects. Its own conclusion is stated without spin: in spite of the negative results of recent pivotal studies in acute ischaemic stroke and traumatic brain injury, there is continuing interest in the neuroprotective properties of citicoline.

We think that sentence is the honest centre of this topic. Two adequately sized trials in the indications where the mechanism should have been most visible did not deliver, and the compound remains in use and under study. Both halves of that are true and neither cancels the other.

3.The Translational Gap, Quantified

There is a detail in the same review that explains part of the disappointment. A systematic review and meta-analysis of preclinical embolic stroke models found that citicoline does deliver neuroprotection in animals — but that the effect is stronger for reduction of infarct volume than for neurological outcome.

That is the translational gap made visible. The compound reliably protects tissue as measured by a scan, and less reliably changes what the animal can do. A clinical trial measures what the patient can do.

4.The Species Difference Nobody Mentions

This is the most interesting thing we found, and it belongs in any serious discussion of the compound.

Citicoline is broken down before absorption and reassembled afterwards, so what reaches the circulation is not the intact molecule but its components. In rodents, that means cytidine. In humans, the CNS Drugs review records that investigators failed to detect any significant quantities of cytidine in human blood, either before or after citicoline intake.

Humans convert it to uridine instead. So the rodent experiments — on which much of the mechanistic case rests — are testing a slightly different biochemical situation from the one that occurs in a person taking the same compound. It is not that the animal work is wrong; it is that one of its inputs differs.

This is also why the uridine story and the citicoline story are the same story in humans, a point we take up in the companion article on uridine.

5.Where Something Positive Has Been Reported

The picture is not uniformly negative, and a review that presented it that way would be as misleading as the marketing.

The IDEALE study examined citicoline in mild vascular cognitive impairment and reported effectiveness and safety in that population. A 2020 systematic review in Nutrients surveying citicoline across neurological disorders concluded that it has a wide range of uses in neurological conditions, while noting for stroke specifically that its role remains unclear and that a meta-analysis found significant heterogeneity between earlier studies and the ICTUS result.

Ophthalmology is where the evidence looks strongest. Multiple reviews describe citicoline as a neuroprotector with effects in glaucomatous disease, an indication far removed from cognitive enhancement but relevant because it demonstrates the compound does something measurable in human neural tissue.

Dose-response signals appear in places too, with improvements reported as more marked at doses of 2,000 mg per day and above — well beyond what any supplement provides.

6.The Safety Record

One thing is not in dispute. A meta-analysis of placebo-controlled trials comparing 1,652 actively treated with 686 placebo-treated participants found the overall frequency of adverse effects comparable between groups, and a study in 4,191 Korean stroke patients found no significant adverse events.

That is a genuinely strong safety dataset by the standards of this category, and it is worth stating clearly precisely because we are being sceptical about efficacy. Well tolerated and not demonstrably effective for a given endpoint are separate findings, and both are here.

7.How We Read It

Citicoline occupies an unusual position: better studied than almost anything else in cognitive supplementation, and studied mostly in populations and at doses that do not describe the person buying it.

The mechanism is real and the compound reaches the brain. The safety data are extensive. The two largest trials in acute brain injury were negative. The positive results come from smaller studies in specific clinical populations, and the strongest evidence of neural effect comes from ophthalmology.

None of that adds up to a claim about a healthy adult doing knowledge work, and we have not seen a trial that addresses that person directly. Anyone telling you otherwise is extrapolating past the evidence, and it is worth knowing which parts they skipped.

Editorial Comment

Citicoline is in Clarity, and we have just spent an article explaining why its clinical record is weaker than the category implies. That is deliberate. A brand that publishes only the supportive half of the evidence on its own ingredient is not describing a formulation, it is advertising one.

No authorised health claim exists for citicoline in the EU, so we make none. What we can say is why it is in the formula: the precursor model, the human pharmacology, and a safety record that is unusually well characterised.